BioIntelliSense manufactures small viscous sensors that can monitor the vital signs of patients. The company recently raised $45 million in funding.Image source: bio-intelligence
As a legislator Weigh some banknotes This will expand telemedicine coverage, and a start-up company that makes sticker-type devices for remote patient monitoring has recently received a lot of funding.
BioIntelliSense, located in Golden, Colorado, was approved by the FDA in 2019, and its viscous sensor can be used to monitor a patient’s heart rate, respiratory rate, and skin temperature when prescribed by a clinician. It recently raised $45 million in a Series B financing led by Chimera, an Abu Dhabi-based investment company, and several healthcare supporters including Royal Philips, Fresenius and UCHealth.
BioIntelliSense was founded in 2018 by Dr. James Mault, a former cardiac surgeon at UCHealth, Colorado. Mault said in a press release that the startup will use the new funds to develop more medical-grade wearable devices and data services.
University of California Health Is an early supporter of startups, Established a partnership with BioIntelliSense a few months before the pandemic began to monitor patients at home before and after surgery. Dr. Richard Zane, chief innovation officer of UC Health, said at a press conference that the hospital system is currently using BioIntelliSense equipment to monitor patient deterioration so that early intervention can be made.
At the same time, Philips Have a business partnership And biological intelligence. It integrates the company’s equipment into its platform to monitor patients in hospitals and homes.
For example, a healthcare network used the device to develop multiple programs, including home monitoring of patients with hypertension, diabetes, congestive heart failure, and other diseases, as well as monitoring of Covid-19 patients.
